title: Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.
abstract: Gaucher disease is caused by defective activity of glucocerebrosidase. The resulting accumulation of glucocerebroside in the lysosomes of visceral macrophages in various tissue and organ compartments leads to multiple manifestations, including hepatosplenomegaly, anemia, thrombocytopenia, growth retardation and skeletal disease. The most prevalent form of Gaucher disease is the non-neuronopathic (type 1) variant, which lacks primary involvement of the central nervous system. Traditionally, this has been referred to as the 'adult type'; however, 66% of individuals with symptomatic non-neuronopathic Gaucher disease manifest in childhood. Onset in childhood is usually predictive of a severe, rapidly progressive phenotype and children with non-neuronopathic Gaucher disease are at high risk for morbid complications. Enzyme therapy with recombinant human glucocerebrosidase in childhood can restore health in reversible manifestations and prevent the development of irreversible symptoms. A heightened focus on pediatric Gaucher disease is therefore needed. Although some correlation has been found between genotype and phenotype, mutation analysis is of limited value in disease prognosis. Management of pediatric Gaucher disease should be underpinned by a thorough assessment of the phenotype at baseline with regular monitoring thereafter. Excluding neuronopathic disease is recommended as the first step. Subsequently, baseline evaluation should focus on staging of different storage tissues, particularly the bone the involvement of which results in the greatest long-term morbidity. These organ assessments are recommended because bone disease severity may not correlate with disease severity in other organs and vice versa. In addition, different organs may respond differently to therapy. Initial assessment of each organ system can enable setting of realistic and individualized goals.
  
  
  CONCLUSIONS
  A thorough approach to baseline assessment will improve the understanding of childhood Gaucher disease, optimizing management to minimize impairment of growth and development and prevent irreversible symptoms.
authors.affiliation: Division and Program in Human Genetics, Children's Hospital Research Foundation, Cincinnati, OH 45229-3039, USA. greg.grabowski@chmcc.org
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Grabowski
authors.forename: Generoso
authors.initials: G
authors.lastname: Andria
authors.forename: Antonio
authors.initials: A
authors.lastname: Baldellou
authors.forename: Pauline E
authors.initials: PE
authors.lastname: Campbell
authors.forename: Joel
authors.initials: J
authors.lastname: Charrow
authors.forename: Ian J
authors.initials: IJ
authors.lastname: Cohen
authors.forename: Chris M
authors.initials: CM
authors.lastname: Harris
authors.forename: Paige
authors.initials: P
authors.lastname: Kaplan
authors.forename: Eugen
authors.initials: E
authors.lastname: Mengel
authors.forename: Miguel
authors.initials: M
authors.lastname: Pocovi
authors.forename: Ashok
authors.initials: A
authors.lastname: Vellodi
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D032921:Consensus; D005776:Gaucher Disease / Q000145:classification / Q000175:diagnosis / Q000503:physiopathology; D005838:Genotype; D006801:Humans; D007223:Infant; D008875:Middle Aged; D011788:Quality of Life